BIOMAT Database Logo BIOMAT Database Logo

Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency. 2011

T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Division of Cell Biology & Physiology, Laboratory of Clinical & Experimental Neuroscience, Indian Institute of Chemical Biology (CSIR), 4 Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India.

Hyoscyamus species is one of the four plants used in Ayurveda for the treatment of Parkinson's disease (PD). Since Hyoscyamus niger was found to contain negligible levels of L-DOPA, we evaluated neuroprotective potential, if any, of characterized petroleum ether and aqueous methanol extracts of its seeds in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD in mice. Air dried authenticated H. niger seeds were sequentially extracted using petroleum ether and aqueous methanol and were characterized employing HPLC-electrochemistry and LCMS. Parkinsonian mice were treated daily twice with the extracts (125-500 mg/kg, p.o.) for two days and motor functions and striatal dopamine levels were assayed. Administration of the aqueous methanol extract (containing 0.03% w/w of L-DOPA), but not petroleum ether extract, significantly attenuated motor disabilities (akinesia, catalepsy and reduced swim score) and striatal dopamine loss in MPTP treated mice. Since the extract caused significant inhibition of monoamine oxidase activity and attenuated 1-methyl-4-phenyl pyridinium (MPP+)-induced hydroxyl radical (·OH) generation in isolated mitochondria, it is possible that the methanolic extract of Hyoscyamus niger seeds protects against parkinsonism in mice by means of its ability to inhibit increased ·OH generated in the mitochondria.

UI MeSH Term Description Entries
D008297 Male Males
D008515 Medicine, Ayurvedic The traditional medicine which is based on customs, beliefs, and practices of the Hindu culture. Ayurvedic Medicine,Medicine, Hindu,Siddha Medicine,Hindu Medicine,Medicine, Siddha
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000432 Methanol A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness. Alcohol, Methyl,Carbinol,Sodium Methoxide,Wood Alcohol,Alcohol, Wood,Methoxide, Sodium,Methyl Alcohol

Related Publications

T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Cardiovascular inhibitory effects of Hyoscyamus niger.
May 2008, Methods and findings in experimental and clinical pharmacology,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds.
February 2002, Journal of natural products,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Phytotoxicity of lignanamides isolated from the seeds of Hyoscyamus niger.
February 2012, Journal of agricultural and food chemistry,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
A new steroidal glycoside from the seeds of Hyoscyamus niger.
January 2013, Natural product research,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Diamine Oxidase from Cultured Roots of Hyoscyamus niger: Its Function in Tropane Alkaloid Biosynthesis.
May 1990, Plant physiology,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Free-radical-scavenging and xanthine oxidase inhibitory constituents from Stereospermum personatum.
November 2005, Journal of natural products,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Comparative radical scavenging and antidiabetic activities of methanolic extract and fractions from Achillea ligustica ALL.
September 2005, Biological & pharmaceutical bulletin,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Hyosgerin, a new optically active coumarinolignan, from the seeds of Hyoscyamus niger.
April 2006, Chemical & pharmaceutical bulletin,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Apoptotic and free radical scavenging properties of the methanolic extract of Gentianella alborosea.
September 2006, Fitoterapia,
T Sengupta, and J Vinayagam, and N Nagashayana, and B Gowda, and P Jaisankar, and K P Mohanakumar
Radical scavenging and gastroprotective activity of methanolic extract of Gmelina arborea stem bark.
January 2016, Journal of Ayurveda and integrative medicine,
Copied contents to your clipboard!